Rabbit anti-Human GALE Polyclonal Antibody | anti-GALE antibody

GALE antibody

Cat. Num. AAA9408565

• Gene Names: GALE; SDR1E1
• Reactivity: Human
• Applications: Western Blot, Immunofluorescence
• Purity: Antibodies were purified by affinity purification using immunogen.
• Synonyms: GALE; Polyclonal Antibody; GALE antibody; SDR1E1; anti-GALE antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Specificity: The antibody detects endogenous level of total GALE antibody.
• Purity/Purification: Antibodies were purified by affinity purification using immunogen.
• Form/Format: Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Concentration: 1.0 mg/ml (varies by lot)
• Sequence Length: 348

• Applicable Applications for anti-GALE antibody: Western Blot (WB), Immunofluorescence (IF)
• Application Notes: Western blotting: 1:500 - 1:2000; Immunofluorescence: 1:50 - 1:200
• Immunogen Type: Recombinant Protein
• Immunogen Description: Recombinant protein of human GALE.
• Target Name: GALE
• Preparation and Storage: Store at -20 degree C

Western Blot (WB)

(Western blot analysis of extracts of various cell lines, using GALE antibody.)

Immunofluorescence (IF)

(Immunofluorescence analysis of A549 cell using GALE antibody. Blue: DAPI for nuclear staining.)

Related Product Information for anti-GALE antibody

This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified.

Product Categories/Family for anti-GALE antibody

Total protein Ab

NCBI and Uniprot Product Information

• NCBI GI #: 56237023
• NCBI GeneID: 2582
• NCBI Accession #: NP_000394.2
• NCBI GenBank Nucleotide #: NM_000403.3
• UniProt Accession #: Q14376; Q38G75; Q86W41; Q9BVE3; Q9UJB4; A0A024RAH5; B3KQ39
• Molecular Weight: 30,180 Da
• NCBI Official Full Name: UDP-glucose 4-epimerase
• NCBI Official Synonym Full Names: UDP-galactose-4-epimerase
• NCBI Official Symbol: GALE
• NCBI Official Synonym Symbols: SDR1E1
• NCBI Protein Information: UDP-glucose 4-epimerase
• UniProt Protein Name: UDP-glucose 4-epimerase
• Protein Family: Galectin
• UniProt Gene Name: GALE
• UniProt Synonym Gene Names: UDP-GlcNAc 4-epimerase
• UniProt Entry Name: GALE_HUMAN

NCBI Description

This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified. [provided by RefSeq, Jul 2008]

Uniprot Description

GALE: Catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose and the epimerization of UDP-N-acetylglucosamine to UDP-N- acetylgalactosamine. Defects in GALE are the cause of epimerase-deficiency galactosemia (EDG); also known as galactosemia type 3. Clinical features include early-onset cataracts, liver damage, deafness and mental retardation. There are two clinically distinct forms of EDG. (1) A benign, or 'peripheral' form with no detectable GALE activity in red blood cells and characterized by mild symptoms. Some patients may suffer no symptoms beyond raised levels of galactose-1-phosphate in the blood. (2) A much rarer 'generalized' form with undetectable levels of GALE activity in all tissues and resulting in severe features such as restricted growth and mental development. Belongs to the sugar epimerase family.

Protein type: Isomerase; EC 5.1.3.2; Carbohydrate Metabolism - galactose; Carbohydrate Metabolism - amino sugar and nucleotide sugar; EC 5.1.3.7

Chromosomal Location of Human Ortholog: 1p36-p35

Cellular Component: cytosol

Molecular Function: UDP-N-acetylglucosamine 4-epimerase activity; protein homodimerization activity; UDP-glucose 4-epimerase activity; coenzyme binding

Biological Process: galactose catabolic process; carbohydrate metabolic process; pathogenesis

Disease: Galactose Epimerase Deficiency